A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...

The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the ...

A main obstacle to an HIV cure is that viral DNA integrates into the chromosomes of memory T cells (blue), which evade ...

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

In a ceremony held last month, the 2024 Louisa Gross Horwitz Prize was awarded to Wesley Sundquist, PhD, Leo T. and Barbara K ...